Core Viewpoint - A class action has been filed against Mereo BioPharma Group plc for allegedly misleading investors regarding the Phase 3 ORBIT and COSMIC studies for setrusumab, which did not meet their primary endpoints, leading to significant financial losses for shareholders [1][2][3]. Group 1: Allegations and Misleading Information - The complaint alleges that Mereo BioPharma provided investors with overly optimistic statements about the expected results of the Phase 3 ORBIT and COSMIC studies for setrusumab, claiming it would reduce annualized fracture rates [2]. - It is claimed that while Mereo expressed confidence in the studies, they concealed material adverse facts about the true state of the ORBIT and COSMIC programs, which ultimately failed to meet their primary endpoints [2]. Group 2: Impact on Stock Price - Following the announcement on December 29, 2025, that neither the ORBIT nor COSMIC studies met their primary endpoint, Mereo's American Depository Shares (ADS) plummeted from $2.31 per share to $0.29 per share, marking a decline of over 87.7% [3]. Group 3: Class Action Participation - Shareholders may be eligible to participate in the class action against Mereo BioPharma, with a deadline to submit papers to serve as lead plaintiff by April 6, 2026 [4]. - Shareholders do not need to participate in the case to be eligible for recovery and can remain absent class members if they choose [4].

Core Viewpoint - A class action lawsuit has been filed against Mereo BioPharma Group PLC, alleging that the company made misleading statements regarding its clinical trials for setrusumab, leading to significant financial losses for investors when the trials failed to meet their primary endpoints [1]. Company Overview - Mereo BioPharma Group PLC is a biopharmaceutical company based in London, UK, focused on developing therapies for rare and serious diseases [1]. Legal Proceedings - The class action lawsuit is on behalf of investors who purchased American Depositary Shares (ADS) from June 5, 2023, to December 26, 2025, with a deadline of April 6, 2026, for investors to seek lead plaintiff status [1]. - The lawsuit claims that Mereo issued overly positive statements about its ORBIT and COSMIC Phase 3 clinical trials for setrusumab, which ultimately did not achieve their primary endpoint of reducing the annualized clinical fracture rate [1]. Financial Impact - Following the disclosure on December 29, 2025, that the clinical trials did not meet their primary endpoints, Mereo's ADS price plummeted over 87%, from $2.31 per share on December 26, 2025, to $0.29 per share on December 29, 2025 [1].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Mereo BioPharma Group plc due to alleged violations of federal securities laws related to misleading statements about clinical trial results [2][4]. Group 1: Legal Investigation - The law firm is encouraging investors who suffered losses in Mereo BioPharma to contact them for discussing legal options [1]. - A federal securities class action has been filed against Mereo, with a deadline of April 6, 2026, for investors to seek the role of lead plaintiff [2][7]. - The firm has a history of recovering hundreds of millions of dollars for investors since its establishment in 1995 [3]. Group 2: Clinical Trial Results - Mereo announced on December 29, 2025, that two Phase 3 studies of setrusumab failed to meet their primary endpoints of reducing annualized clinical fracture rates compared to placebo and bisphosphonates [5]. - Despite the primary endpoint misses, the trials showed statistically significant improvements in bone mineral density on secondary endpoints, and no new safety concerns were identified [5]. - Following the announcement, Mereo's stock price plummeted by $2.02 per share, or 87.64%, closing at $0.28 per share [6].

Core Viewpoint - A class action lawsuit has been filed against Mereo BioPharma Group plc, alleging securities fraud and unlawful business practices by the company and certain officers and/or directors [2]. Group 1: Lawsuit Details - Investors are encouraged to contact Pomerantz LLP for participation in the class action, with a deadline to apply as Lead Plaintiff by April 6, 2026 [2]. - A copy of the Complaint related to the class action can be accessed at Pomerantz's website [2]. Group 2: Company Performance and Stock Impact - On July 9, 2025, Mereo and Ultragenyx Pharmaceutical Inc. announced that the Phase 3 Orbit study was progressing towards a final analysis, leading to a significant drop in Mereo's ADR price by $1.25, or 42.52%, closing at $1.69 on July 10, 2025 [4]. - On December 29, 2025, Mereo reported that neither the Orbit nor the Cosmic Phase 3 studies achieved statistical significance, resulting in a drastic decline in ADR price by $2.02, or 87.7%, closing at $0.29 [5].

New York, New York--(Newsfile Corp. - February 17, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of American Depositary Shares ("ADS") of Mereo BioPharma Group plc (NASDAQ: MREO) between June 5, 2023 and December 26, 2025, inclusive (the "Class Period"), of the important April 6, 2026 lead plaintiff deadline.SO WHAT: If you purchased Mereo ADSs during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contin ...

ATLANTA, Feb. 17, 2026 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Mereo BioPharma Group plc (“Mereo” or the “Company”) (NASDAQ: MREO). The lawsuit alleges that Defendants issued false and misleading statements and/or failed to disclose material adverse facts, including allegations that Defendants concealed and misrepresented facts regarding setrusumab’s ability to achieve statistical significance for the primary endpoints in both the ORBIT and COSMIC studies. If you purcha ...

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of American Depositary Shares (ADS) of Mereo BioPharma Group plc, covering the period from June 5, 2023, to December 26, 2025, due to alleged misleading statements regarding the company's clinical studies [1][5][6]. Group 1: Lawsuit Details - The lawsuit claims that Mereo BioPharma provided investors with optimistic information about the Phase 3 Orbit and COSMIC studies for setrusumab in Osteogenesis Imperfecta (OI), suggesting confidence in the drug's efficacy [5]. - Defendants allegedly made positive statements while concealing adverse facts about the Phase 3 programs, which did not meet their primary endpoints, leading to artificially inflated prices for Mereo's ADSs [6]. Group 2: Class Action Participation - Investors who purchased Mereo ADSs during the specified Class Period may be eligible for compensation without incurring out-of-pocket fees through a contingency fee arrangement [2]. - To join the class action, interested parties can visit the provided link or contact the law firm directly for more information [3][7].

Core Viewpoint - A class action lawsuit has been announced by Rosen Law Firm on behalf of purchasers of American Depositary Shares (ADS) of Mereo BioPharma Group plc, covering the period from June 5, 2023, to December 26, 2025, due to alleged misleading statements regarding the company's clinical studies [1][5][6]. Group 1: Lawsuit Details - The lawsuit claims that Mereo BioPharma provided investors with optimistic information about the Phase 3 Orbit and COSMIC studies for setrusumab in Osteogenesis Imperfecta (OI), suggesting confidence in the drug's ability to reduce annualized fracture rates [5]. - It is alleged that while making these positive statements, Mereo BioPharma concealed material adverse facts about the Phase 3 programs, which ultimately did not meet their primary endpoints [6]. - The misleading statements led to investors purchasing Mereo's ADSs at artificially inflated prices, resulting in damages when the true information became public [6]. Group 2: Participation Information - Investors who purchased Mereo ADSs during the class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To join the class action, interested parties can visit the provided link or contact the law firm directly for more information [3][7].

Core Viewpoint - Mereo BioPharma Group plc is facing potential legal claims due to alleged violations of federal securities laws related to misleading statements about its Phase 3 clinical trials, which failed to meet primary endpoints [4][5]. Group 1: Legal Investigation and Class Action - Faruqi & Faruqi, LLP is investigating claims against Mereo BioPharma and has set an April 6, 2026 deadline for investors to seek the role of lead plaintiff in a federal securities class action [2]. - The firm encourages investors who suffered losses in Mereo to contact them directly to discuss their legal options [1][8]. Group 2: Clinical Trial Results - Mereo announced that two Phase 3 studies of setrusumab did not meet their primary endpoints of reducing annualized clinical fracture rates compared to placebo and bisphosphonates [5]. - Despite the primary endpoint failures, the trials showed statistically significant improvements in bone mineral density on secondary endpoints, and no new safety concerns were identified [5]. Group 3: Market Reaction - Following the announcement of the failed trials, Mereo's stock price dropped by $2.02 per share, a decline of 87.64%, closing at $0.28 per share on December 29, 2025 [6].

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of American Depositary Shares (ADS) of Mereo BioPharma Group plc, covering the period from June 5, 2023, to December 26, 2025, due to alleged misleading statements regarding the company's clinical studies [1][5][6]. Group 1: Lawsuit Details - The lawsuit claims that Mereo BioPharma provided investors with optimistic information about the Phase 3 Orbit and COSMIC studies for setrusumab, suggesting it would reduce annualized fracture rates [5]. - It is alleged that while making these positive statements, Mereo BioPharma concealed material adverse facts about the Phase 3 programs, which did not meet their primary endpoints [6]. - The misleading information led to investors purchasing Mereo's ADSs at artificially inflated prices, resulting in damages when the true details were revealed [6]. Group 2: Participation Information - Investors who purchased Mereo ADSs during the class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To join the class action, interested parties can visit the provided link or contact the law firm directly for more information [3][7]. - A lead plaintiff must be appointed by April 6, 2026, to represent other class members in the litigation [1][3]. Group 3: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company [4]. - The firm has consistently ranked highly in securities class action settlements and has recovered hundreds of millions of dollars for investors [4].